These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 19284067)

  • 21. Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trial.
    Lemos PA; Moulin B; Perin MA; Oliveira LA; Arruda JA; Lima VC; Lima AA; Caramori PR; Medeiros CR; Barbosa MR; Brito FS; Ribeiro EE; Martinez EE;
    Catheter Cardiovasc Interv; 2009 Nov; 74(5):665-73. PubMed ID: 19670303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Five-year clinical outcomes of a polymer-free sirolimus-eluting stent versus a permanent polymer paclitaxel-eluting stent: final results of the intracoronary stenting and angiographic restenosis - test equivalence between two drug-eluting stents (ISAR-TEST) trial.
    King L; Byrne RA; Mehilli J; Schömig A; Kastrati A; Pache J
    Catheter Cardiovasc Interv; 2013 Jan; 81(1):E23-8. PubMed ID: 22431239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EuroSCORE is a good global predictor of long-term outcomes in high-risk but not in low-risk patients after unprotected left main angioplasty.
    Rekik S; Brunet J; Bayet G; Hager FX; Meille L; Quatre JM; Sainsous J
    Catheter Cardiovasc Interv; 2011 Apr; 77(5):625-32. PubMed ID: 20578163
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Percutaneous coronary intervention with oral sirolimus and bare metal stents has comparable safety and efficacy to treatment with drug eluting stents, but with significant cost saving: long-term follow-up results from the randomised, controlled ORAR III (Oral Rapamycin in ARgentina) study.
    Rodriguez AE; Maree A; Tarragona S; Fernandez-Pereira C; Santaera O; Rodriguez Granillo AM; Rodriguez-Granillo GA; Russo-Felssen M; Kukreja N; Antoniucci D; Palacios IF; Serruys PW;
    EuroIntervention; 2009 Jun; 5(2):255-64. PubMed ID: 20449934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Five-year clinical follow-up of unprotected left main bifurcation lesion stenting: one-stent versus two-stent techniques versus double-kissing crush technique.
    Chen SL; Zhang Y; Xu B; Ye F; Zhang J; Tian N; Liu Z; Qian X; Ding S; Li F; Zhang A; Liu Y; Lin S
    EuroIntervention; 2012 Nov; 8(7):803-14. PubMed ID: 23171801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug-eluting stents for the treatment of ostial coronary lesions: comparison of sirolimus-eluting stent with paclitaxel-eluting stent.
    Chen J; Li JJ; Chen JL; Qiao SB; Xu B; Yang YJ; Gao RL; Qin XW; Yuan JQ; Yao M; Wu YJ; Liu HB; Dai J; You SJ
    Coron Artery Dis; 2008 Nov; 19(7):507-11. PubMed ID: 18923247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of coronary artery bypass surgery and percutaneous drug-eluting stent implantation for treatment of left main coronary artery stenosis.
    White AJ; Kedia G; Mirocha JM; Lee MS; Forrester JS; Morales WC; Dohad S; Kar S; Czer LS; Fontana GP; Trento A; Shah PK; Makkar RR
    JACC Cardiovasc Interv; 2008 Jun; 1(3):236-45. PubMed ID: 19463306
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry.
    Novack V; Cutlip D; Kleiman N; Pencina M; Mauri L; Yen CH; Berger P; Goldberg S; Kellett M; Waksman R; Hong M; Raizner AE; Cohen DJ
    JACC Cardiovasc Interv; 2009 Aug; 2(8):767-75. PubMed ID: 19695546
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Five-year clinical outcomes of sirolimus-eluting versus paclitaxel-eluting stents in high-risk patients.
    Birkmeier KA; Kastrati A; Byrne RA; Holle H; Schulz S; Tiroch K; Kufner S; Massberg S; Laugwitz KL; Schömig A; Mehilli J
    Catheter Cardiovasc Interv; 2011 Mar; 77(4):494-501. PubMed ID: 20824758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials.
    Cassese S; Kufner S; Xhepa E; Byrne RA; Kreutzer J; Ibrahim T; Tiroch K; Valgimigli M; Tölg R; Fusaro M; Schunkert H; Laugwitz KL; Mehilli J; Kastrati A
    Clin Res Cardiol; 2016 Jul; 105(7):575-84. PubMed ID: 26689707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Percutaneous treatment with drug-eluting stent vs bypass surgery in patients suffering from chronic stable angina with multivessel disease involving significant proximal stenosis in left anterior descending artery.
    Yan Q; Changsheng M; Shaoping N; Xiaohui L; Junping K; Qiang L; Xin D; Rong H; Yin Z; Changqi J; Jiahui W; Xinmin L; Jianzeng D; Fang C; Yujie Z; Shuzheng L; Fangjiong H; Chengxiong G; Xuesi W
    Circ J; 2009 Oct; 73(10):1848-55. PubMed ID: 19713656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Five-year clinical outcomes after coronary stenting of chronic total occlusion using sirolimus-eluting stents: insights from the rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital-(Research) Registry.
    Shen ZJ; García-García HM; Garg S; Onuma Y; Schenkeveld L; van Domburg RT; Serruys PW;
    Catheter Cardiovasc Interv; 2009 Dec; 74(7):979-86. PubMed ID: 19753636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unprotected left main coronary artery stenting with zotarolimus (Endeavor) drug-eluting stents: a single center retrospective experience.
    Simard T; Hibbert B; Chong AY; Ruchin P; Le May M; Labinaz M; Froeschl M; So D; Glover C; Marquis JF; O'Brien E
    Catheter Cardiovasc Interv; 2012 Aug; 80(2):E15-22. PubMed ID: 21805580
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Crush stenting with drug-eluting stents: relevance of coronary bifurcation lesion location on angiographic and clinical outcomes.
    Chen SL; Zhang JJ; Ye F; Liu ZZ; Zhu ZS; Lin S; Tian NL; Fang WY; Chen YD; Sun XW; Wei M; Shan SJ; Kan J; Qian J; Yang S; Yuan ZB; Kwan TW; Hu DY
    Clin Cardiol; 2010 Dec; 33(12):E32-9. PubMed ID: 20857513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early and long-term results of percutaneous coronary intervention for unprotected left main trifurcation disease.
    Sheiban I; Gerasimou A; Bollati M; Biondi-Zoccai G; Sciuto F; Omedé P; Sillano D; Trevi GP; Moretti C
    Catheter Cardiovasc Interv; 2009 Jan; 73(1):25-31. PubMed ID: 19089932
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial.
    Vink MA; Dirksen MT; Suttorp MJ; Tijssen JG; van Etten J; Patterson MS; Slagboom T; Kiemeneij F; Laarman GJ
    JACC Cardiovasc Interv; 2011 Jan; 4(1):24-9. PubMed ID: 21251625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of unprotected left main disease with drug-eluting stents in patients at high risk for coronary artery bypass grafting.
    Barlis P; Horrigan M; Elis S; Chan R; Wong M; Farouque O; Proimos G; Ajani AE; Clark DJ
    Cardiovasc Revasc Med; 2007; 8(2):84-9. PubMed ID: 17574165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. First generation versus new generation drug-eluting stents for the treatment of ostial/midshaft lesions in unprotected left main coronary artery: the Milan and New-Tokyo (MITO) registry.
    Naganuma T; Chieffo A; Takagi K; Panoulas VF; Mitomo S; Sticchi A; Latib A; Miyazaki T; Sato K; Costopoulos C; Fujino Y; Montorfano M; Carlino M; Nakamura S; Colombo A
    Catheter Cardiovasc Interv; 2015 Feb; 85(3):E63-9. PubMed ID: 25099758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two-year outcomes of the sirolimus-eluting stent according to unprotected left main lesion.
    Kim U; Park JS; Seol SH; Yang TH; Kim SM; Kim DK; Kim DI; Kim DS; Lee WJ; Lee SH; Hong GR; Shin DG; Kim YJ; Shim BS; Cho YK; Kim HS; Nam CW; Hur SH; Kim KB; Kim YN
    Clin Cardiol; 2009 Jun; 32(6):332-6. PubMed ID: 19569064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.